Blood filters in children with COVID-19 and acute kidney injury: A review


Raina R., Sethi S. K. , Chakraborty R., Singh S., Teo S., Khooblall A., ...More

THERAPEUTIC APHERESIS AND DIALYSIS, vol.26, pp.566-582, 2022 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 26
  • Publication Date: 2022
  • Doi Number: 10.1111/1744-9987.13793
  • Title of Journal : THERAPEUTIC APHERESIS AND DIALYSIS
  • Page Numbers: pp.566-582
  • Keywords: blood filters, COVID-19, CVVHDF, CytoSorb, oXiris, HIGH-VOLUME HEMOFILTRATION, CONTINUOUS VENOVENOUS HEMODIAFILTRATION, COUPLED PLASMA FILTRATION, POLYMYXIN-B HEMOPERFUSION, PEDIATRIC-PATIENTS, CYTOKINE STORM, SEPTIC SHOCK, SEPSIS, MORTALITY, REMOVAL

Abstract

COVID-19 has challenged the global healthcare system through rapid proliferation and lack of existing treatment resulting in over 180 million cases and 3.8 million deaths since December 2019. Although pediatric patients only comprise 1%-2% of diagnosed cases, their incidence of acute kidney injury ranges from 8.2% to 18.2% compared to 49% in adults. Severe infection, initiated by dysregulated host response, can lead to multiorgan failure. In this review, we focus on the use of various blood filters approved for use in pediatric kidney replacement therapy to mitigate adverse effects of severe illness. Therapeutic effects of these blood filters range from cytokine removal (CytoSorb, HA330, HCO/MCO), endotoxin removal (Toraymyxin, CPFA), both cytokine and endotoxin removal (oXiris), and nonspecific removal of proteins (PMMA) that have already been established and can be used to mitigate the various effects of the cytokine storm syndrome in COVID-19.